Multiple sclerosis: Oral laquinimod for MS - Bringing the brain into focus

Nature Reviews Neurology

Volumn 9, Issue 12, 2013, Pages 664-665

  Brück, Wolfgang ^a   Vollmer, Timothy ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; LAQUINIMOD; PLACEBO;

ANTIGEN PRESENTING CELL; BRAIN DAMAGE; BRAIN SIZE; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENCE RISK; WHITE MATTER LESION;

BRAIN; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; QUINOLONES;

EID: 84890126970     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2013.234     Document Type: Note

References (8)

1. Brück, W. et al. Therapeutic decisions in multiple sclerosis: Moving beyond efficacy. JAMA Neurol. http://dx.doi.org/10.1001/jamaneurol.2013.3510
2. Comi, G. et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med. 366, 1000-1009 (2012)
3. Filippi, M. et al. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J. Neurol. Neurosurg. Psychiatry http://dx.doi.org/10.1136/jnnp2013306132
4. Brück, W. et al. Reduced astrocytic NFB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 124, 411-424 (2012)
5. Jolivel, V. et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain 136, 1048-1066 (2013)
6. Schulze-Topphoff, U. et al. Laquinimod, a quinoline3carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS ONE 7, e33797 (2012)
7. Brück, W. & Zamvil, S. S. Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis. Expert Rev. Clin. Pharmacol. 5, 245-256 (2012)
8. Lassmann, H. Pathology and disease mechanisms in different stages of multiple sclerosis. J. Neurol. Sci. 333, 1-4 (2013)